All Outputs (11)

Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study (2022)
Journal Article
Liu, Z., Le, K., Zhou, X., Alexander, J. L., Lin, S., Bewshea, C., …Powell, N. (2023). Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study. The Lancet Gastroenterology & Hepatology, 8(2), 145-156. https://doi.org/10.1016/S2468-1253%2822%2900389-2

Background
Anti-TNF drugs, such as infliximab, are associated with attenuated antibody responses after SARS-CoV-2 vaccination. We aimed to determine how the anti-TNF drug infliximab and the anti-integrin drug vedolizumab affect vaccine-induced neutr... Read More about Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study.

The relationship between Central Nervous System morphometry changes and key symptoms in Crohn’s disease (2022)
Journal Article
Thapaliya, G., Eldeghaidy, S., Asghar, M., McGing, J., Radford, S., Francis, S., & Moran, G. W. (2022). The relationship between Central Nervous System morphometry changes and key symptoms in Crohn’s disease. Brain Imaging and Behavior, 17(2), 149–160. https://doi.org/10.1007/s11682-022-00742-6

Alterations in grey matter volume (GMV) and cortical thickness (CT) in Crohn’s disease (CD) patients has been previously documented. However, the findings are inconsistent, and not a true representation of CD burden, as only CD patients in remission... Read More about The relationship between Central Nervous System morphometry changes and key symptoms in Crohn’s disease.

Post-inflammatory Polyp Burden as a Prognostic Marker of Disease-outcome in Patients with Inflammatory Bowel Disease (2022)
Journal Article
Ellul, P., Schembri, J., Vella Baldacchino, A., Molnár, T., Resal, T., Allocca, M. A., …Katsanos, K. (2023). Post-inflammatory Polyp Burden as a Prognostic Marker of Disease-outcome in Patients with Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 17(4), 489-496. https://doi.org/10.1093/ecco-jcc/jjac169

BACKGROUND AND AIMS: Post-inflammatory polyps [PIPs] are considered as indicators of previous episodes of severe inflammation and mucosal ulceration. Inflammatory bowel disease [IBD], namely Crohn's disease [CD] and ulcerative colitis [UC], exhibit a... Read More about Post-inflammatory Polyp Burden as a Prognostic Marker of Disease-outcome in Patients with Inflammatory Bowel Disease.

Treatment adaptations and outcomes of patients experiencing inflammatory bowel disease flares during the early COVID-19 pandemic: the PREPARE-IBD multicentre cohort study (2022)
Journal Article
Saifuddin, A., Kent, A. J., Mehta, S. J., Hicks, L. C., Gonzalez, H. A., Segal, J. P., Brookes, M. J., Subramanian, S., Bhala, N., Conley, T. E., Patel, K. V., Lamb, C. A., Walker, G. J., Kennedy, N. A., Sebastian, S., & PREPARE‐IBD Collaborators. (2022). Treatment adaptations and outcomes of patients experiencing inflammatory bowel disease flares during the early COVID-19 pandemic: the PREPARE-IBD multicentre cohort study. Alimentary Pharmacology and Therapeutics, 56(10), 1460-1474. https://doi.org/10.1111/apt.17223

Background:

The COVID-19 pandemic offered a unique opportunity to understand inflammatory bowel disease (IBD) management during unexpected disruption. This could help to guide practice overall.

Aims:

To compare prescribing behaviour for I... Read More about Treatment adaptations and outcomes of patients experiencing inflammatory bowel disease flares during the early COVID-19 pandemic: the PREPARE-IBD multicentre cohort study.

British Society of Gastroenterology interim framework for addressing the COVID-19-related backlog in inflammatory bowel disease colorectal cancer surveillance (2022)
Journal Article
Churchhouse, A. M. D., Moffat, V. E. L., Selinger, C. P., Lamb, C. A., Thornton, M. J., Penman, I., & Din, S. (2023). British Society of Gastroenterology interim framework for addressing the COVID-19-related backlog in inflammatory bowel disease colorectal cancer surveillance. Gut, 72(9), 1631-1634. https://doi.org/10.1136/gutjnl-2022-328309

The impact of Inflammatory Bowel Disease related fatigue on Health-Related Quality of Life: a qualitative semi-structured interview study (2022)
Journal Article
Radford, S. J., Moran, G. W., & Czuber-Dochan, W. (2022). The impact of Inflammatory Bowel Disease related fatigue on Health-Related Quality of Life: a qualitative semi-structured interview study. Journal of Research in Nursing, 27(8), 685-702. https://doi.org/10.1177/17449871211061048

Background: Fatigue is a frequently reported symptom of Inflammatory Bowel Disease (IBD), having a negative impact on Health-Related Quality of Life (HRQoL). Patients’ experiences of this have not been researched in IBD. Methods: Semi-structured inte... Read More about The impact of Inflammatory Bowel Disease related fatigue on Health-Related Quality of Life: a qualitative semi-structured interview study.

Acute effects of prior dietary fat ingestion on postprandial metabolic responses to protein and carbohydrate co-ingestion in overweight and obese men: A randomised crossover trial (2022)
Journal Article
Wilhelmsen, A., Davies, A., Mallinson, J., Pabla, P., Jones, R., Palmer, E. A., …Tsintzas, K. (2022). Acute effects of prior dietary fat ingestion on postprandial metabolic responses to protein and carbohydrate co-ingestion in overweight and obese men: A randomised crossover trial. Clinical Nutrition, 41(8), 1623-1635. https://doi.org/10.1016/j.clnu.2022.06.022

Background: Obesity and insulin resistance are associated with an impaired sensitivity to anabolic stimuli such as dietary protein (anabolic resistance). Omega-3 polyunsaturated fatty acids (n-3 PUFA) may be protective against the deleterious effects... Read More about Acute effects of prior dietary fat ingestion on postprandial metabolic responses to protein and carbohydrate co-ingestion in overweight and obese men: A randomised crossover trial.

Imaging in inflammatory bowel disease: current and future perspectives (2022)
Journal Article
Shaban, N., Hoad, C. L., Naim, I., Alshammari, M., Radford, S. J., Clarke, C., …Moran, G. (2022). Imaging in inflammatory bowel disease: current and future perspectives. Frontline Gastroenterology, 13(e1), E28-E34. https://doi.org/10.1136/flgastro-2022-102117

The use of cross-sectional imaging and ultrasonography has long complemented endoscopic assessment of inflammatory bowel disease (IBD). Clinical symptoms alone are often not enough to assess disease activity, so a reliance on non-invasive techniques... Read More about Imaging in inflammatory bowel disease: current and future perspectives.

Tacrolimus (FK506) for induction of remission in corticosteroid-refractory ulcerative colitis (2022)
Journal Article
Gordon, M., Sinopoulou, V., Akobeng, A. K., Pana, M., Gasiea, R., & Moran, G. W. (2022). Tacrolimus (FK506) for induction of remission in corticosteroid-refractory ulcerative colitis. Cochrane Library, 2022(4), 1-55. https://doi.org/10.1002/14651858.CD007216.pub2

Background: There are a limited number of treatment options for people with corticosteroid-refractory ulcerative colitis. Animal models of inflammatory bowel disease and uncontrolled studies in humans suggest that tacrolimus may be an effective treat... Read More about Tacrolimus (FK506) for induction of remission in corticosteroid-refractory ulcerative colitis.

Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab (2022)
Journal Article
Lin, S., Kennedy, N. A., Saifuddin, A., Sandoval, D. M., Reynolds, C. J., Castro Seoane, R., …Jones, G. (2022). Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab. Nature Communications, 13, Article 1379. https://doi.org/10.1038/s41467-022-28517-z

Anti tumour necrosis factor (anti-TNF) drugs increase the risk of serious respiratory infection and impair protective immunity following pneumococcal and influenza vaccination. Here we report SARS-CoV-2 vaccine-induced immune responses and breakthrou... Read More about Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab.

Ultrasound use to assess Crohn’s disease in the UK: a survey of British Society of Gastroenterology Inflammatory Bowel Disease Group members (2022)
Journal Article
Radford, S. J., Taylor, S. A., & Moran, G. (2022). Ultrasound use to assess Crohn’s disease in the UK: a survey of British Society of Gastroenterology Inflammatory Bowel Disease Group members. Frontline Gastroenterology, 13(6), 471-476. https://doi.org/10.1136/flgastro-2021-102065

Background: Small bowel ultrasound has very good diagnostic accuracy for disease extent, presence and activity in Crohn's Disease, is well tolerated by patients and is cheaper when compared with MRI. However, uptake of ultrasound in the UK is limited... Read More about Ultrasound use to assess Crohn’s disease in the UK: a survey of British Society of Gastroenterology Inflammatory Bowel Disease Group members.